Here’s our latest on two high-growth buys: Eli Lilly & Co. and

Article Excerpt

Long-time readers know that we keep you informed of important news about the stocks we cover. That means highlighting developments that promise to brighten their outlook. Here are two that stand out as buys this month: ELI LILLY & CO. $201.26 is a buy. The stock (New York symbol LLY; TSINetwork Rating: Above Average) (; Shares outstanding: 956.5 million; Market cap: $192.5 billion; Dividend yield: 1.7%) soared to new highs recently after it announced the latest Phase II results for its Alzheimer’s drug donanemab. After 18 months, donanemab slowed patients’ decline in memory and their ability to perform daily activities by 32% when compared with a placebo. Those benefits will need to be confirmed in a larger trial—the latest Lilly data is from just 272 patients. If successful, the drug would prove to be highly lucrative. There are five million Americans currently living with the fatal disease, according to the Alzheimer’s Association. The population is aging, so that figure is likely to move higher in the years…

You are trying to access subscriber-only content.

To read this article, you may subscribe or sign in.
If you are already a subscriber, log in here.

If you wish to become a subscriber, click here. Or you may enjoy access to all our publications when you become a Member of Pat McKeough's Inner Circle Pro.